Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CFO Thomas Catinazzo sold 9,373 shares of the stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $6.24, for a total transaction of $58,487.52. Following the sale, the chief financial officer now directly owns 330,430 shares in the company, valued at $2,061,883.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Thomas Catinazzo also recently made the following trade(s):
- On Monday, April 29th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The stock was sold at an average price of $6.38, for a total transaction of $10,814.10.
Relay Therapeutics Stock Down 1.8 %
Shares of NASDAQ RLAY opened at $6.40 on Tuesday. The firm has a 50-day simple moving average of $6.81 and a 200-day simple moving average of $8.50. The stock has a market capitalization of $849.55 million, a price-to-earnings ratio of -2.42 and a beta of 1.66. Relay Therapeutics, Inc. has a 52 week low of $5.70 and a 52 week high of $13.32.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the stock. JMP Securities restated a “market outperform” rating and set a $24.00 price objective on shares of Relay Therapeutics in a research report on Monday, May 6th. Oppenheimer restated an “outperform” rating and set a $25.00 price objective (down from $33.00) on shares of Relay Therapeutics in a research report on Monday, May 6th. Barclays upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and set a $15.00 target price for the company in a research report on Friday, May 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Relay Therapeutics in a research report on Friday, June 7th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $22.80.
View Our Latest Stock Analysis on RLAY
Institutional Investors Weigh In On Relay Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new stake in Relay Therapeutics during the first quarter worth about $79,000. Virtu Financial LLC purchased a new position in Relay Therapeutics during the first quarter worth about $87,000. Victory Capital Management Inc. purchased a new position in Relay Therapeutics during the fourth quarter worth about $126,000. Quest Partners LLC purchased a new position in Relay Therapeutics during the fourth quarter worth about $147,000. Finally, Los Angeles Capital Management LLC boosted its stake in Relay Therapeutics by 25.7% during the first quarter. Los Angeles Capital Management LLC now owns 13,939 shares of the company’s stock worth $116,000 after buying an additional 2,850 shares during the period. 96.98% of the stock is currently owned by institutional investors and hedge funds.
About Relay Therapeutics
Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.
Further Reading
- Five stocks we like better than Relay Therapeutics
- Stock Sentiment Analysis: How it Works
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Insider Buying Explained: What Investors Need to Know
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What is the S&P 500 and How It is Distinct from Other Indexes
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.